Adventitious Viruses Detected in Biopharmaceutical Bulk Harvest Samples over a 10 Year Period

References

1. 1.↵
   1. Nims R.

   Detection of adventitious viruses in biologicals—A rare occurrence. Dev. Biol. (Basel) 2006, 123, 153–164.

   OpenUrlPubMed
2. 2.↵
   Genzyme press release, 2009, http://www.genzyme.com/corp/media/GENZ%20PR-061609.asp.
3. 3.↵
   1. Oehmig A.,
   2. Büttner M.,
   3. Weiland F.,
   4. Werz W.,
   5. Bergemann K,
   6. Pfaff E.

   Identification of a calicivirus isolate of unknown origin. J. Gen. Virol. 2003, 84 (10), 2837–2845.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   US FDA Points to Consider in the Characterization of Cell Lines Used to Produce Biologics, FDA/CDER. 1993.
5. 5.↵
   International Conference on Harmonisation ICH Q5A (R1). Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. CPMP/ICH/295/95. October 1997.
6. 6.↵
   1. Shepherd A. J.,
   2. Wilson N. J.,
   3. Smith K. T.

   Characterization of endogenous retrovirus in rodent cell lines used for production of biologicals. Biologicals 2003, 31 (4), 251–260.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Spier R. E.

   1. Wiebe M. E.,
   2. Becker F.,
   3. Lazar R.,
   4. May L.,
   5. Casto B.,
   6. Semense M.,
   7. Fautz C.,
   8. Garnick R.,
   9. Miller C.,
   10. Masover G.,
   11. Bergmann D.,
   12. Lubiniecki A. S.

   A Multifaceted Approach To Assure That Recombinant tPA Is Free of Adventitious Virus. In Advances in Animal Cell Biology and Technology for Bioprocesses; Spier R. E., Ed.; Butterworths: London, 1989; pp 68–71.
8. 8.↵
   1. Poiley J. A.,
   2. Nelson R. E.,
   3. Hillesund T.,
   4. Raineri R.

   Susceptibility of CHO-K1 cells to infection by eight adventitious viruses and four retroviruses. In Vitro Toxicol. 1991, 4 (1), 1–12.

   OpenUrl
9. 9.↵
   1. Garnick R. L.

   Experience with viral contamination in cell culture. Dev. Biol. Stand. 1996, 88, 49–56.

   OpenUrlPubMed
10. 10.↵
    US FDA Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. FDA/CDER 1997.
11. 11.↵
    1. Boose J. A.,
    2. Lister D. C.,
    3. Sofer G.

    Virus inactivation in the 1990s—and into the 21st Century. Part 6, Inactivation methods grouped by virus. Biopharm Int. 2003, 16 (4), 42–52, 68.

    OpenUrl
12. 12.↵
    1. Weaver B.

    Evaluation of UVC and HTST media treatment for viral risk mitigation in mammalian cell culture processes. PDA Cell Substrates Workshop, Bethesda, MD, 2009. http://www.pda.org/Presentation/PDA-Cell-Substrate-Workshop/Robert-Weaver.aspx.
13. 13.↵
    1. Schleh M.,
    2. Romanowski P.,
    3. Bhebe P.,
    4. Zhang L.,
    5. Chinniah S.,
    6. Lawrence B.,
    7. Bashiri H.,
    8. Gaduh A.,
    9. Rajurs V.,
    10. Rasmussen B.,
    11. Chuck A.,
    12. Dehghani H.

    Susceptibility of mouse minute virus to inactivation by heat in two cell culture media types. Biotechnol. Prog. 2009, 25 (3), 854–860.

    OpenUrlPubMed
14. 14.↵
    1. Rathore A.,
    2. S.,
    3. Sofer G.

    1. Nims R.,
    2. Presente E.,
    3. Sofer G.,
    4. Phillips C.,
    5. Chang A.

    Adventitious Agents: Concerns and Testing for Biopharmaceuticals. In Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies; Rathore A., S., Sofer G., Eds.; CRC Press/Francis Informa: Boca Raton, FL, 2005; pp 143–167.
15. 15.↵
    1. Nims R. W.,
    2. Dusing SK.,
    3. Hsieh W.-T.,
    4. Lovatt A.,
    5. Reid G. G.,
    6. Onions D.,
    7. Milne E. W.

    Detection of Cache Valley virus in biologics manufactured in CHO cells. BioPharm Int. 2008, 21 (10), 89–94.

    OpenUrl
16. 16.↵
    Code of Federal Regulations: Animals and Animal Products. Title 9, Part 113.53. US Government Printing Office: Washington, DC, 2003.
17. 17.↵
    1. Kurth J.,
    2. Waldmann R.,
    3. Heith J.,
    4. Mausbach K.,
    5. Burian R.

    Efficient inactivation of viruses and mycoplasma in animal sera using UVC irradiation. Dev. Biol. Stand. 1999, 99, 111–118.

    OpenUrlPubMed
18. 18.↵
    1. Gauvin G.,
    2. Nims R

    . Gamma-irradiation of serum for the inactivation of adventitious contaminants. PDA J. Pharm. Sci. Technol. 2010 (this volume).